LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's Disease

LY-3372689 MAGNOLIA Trial (NCT05063539)

Overview

The MAGNOLIA trial is a Phase 2 clinical study evaluating LY-3372689 (zaniglusemab, oglemilide), an oral O-GlcNAcase (OGA) inhibitor developed by [Eli Lilly](/companies/eli-lilly), in patients with early Alzheimer's disease. This is one of the first large-scale clinical trials of an OGA inhibitor in AD[@magnolia].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT05063539 |
| Phase | Phase 2 |
| Status | Completed |
| Drug | LY-3372689 (zaniglusemab) |
| Company | Eli Lilly |
| Indication | Early Alzheimer's Disease (MCI due to AD, mild AD dementia) |
| Enrollment | ~200 patients |
| Duration | 52 weeks treatment |
| Primary Endpoints | Safety, tolerability, biomarker changes |
| Secondary Endpoints | Cognitive measures (ADAS-Cog14, ADCS-MCI-ADL) |

Study Design

Population

• Early AD patients (MCI due to AD or mild AD dementia)
• Confirmed amyloid pathology (PET or CSF)
• MMSE score 20-28
• Age 55-85 years

Treatment Arms

• LY-3372689: Multiple dose levels (oral)
• Placebo: Matching oral dosing
• Duration: 52 weeks

Key Endpoints

• Primary: Safety and tolerability
• Secondary: CSF O-GlcNAc levels, p-tau181, total tau, cognitive measures

Mechanism: OGA Inhibition

LY-3372689 inhibits O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modifications from proteins including tau[@oga_mechanism]:

...

LY-3372689 MAGNOLIA Trial (NCT05063539)

Overview

The MAGNOLIA trial is a Phase 2 clinical study evaluating LY-3372689 (zaniglusemab, oglemilide), an oral O-GlcNAcase (OGA) inhibitor developed by [Eli Lilly](/companies/eli-lilly), in patients with early Alzheimer's disease. This is one of the first large-scale clinical trials of an OGA inhibitor in AD[@magnolia].

Trial Details

| Parameter | Value |
|-----------|-------|
| Trial ID | NCT05063539 |
| Phase | Phase 2 |
| Status | Completed |
| Drug | LY-3372689 (zaniglusemab) |
| Company | Eli Lilly |
| Indication | Early Alzheimer's Disease (MCI due to AD, mild AD dementia) |
| Enrollment | ~200 patients |
| Duration | 52 weeks treatment |
| Primary Endpoints | Safety, tolerability, biomarker changes |
| Secondary Endpoints | Cognitive measures (ADAS-Cog14, ADCS-MCI-ADL) |

Study Design

Population

• Early AD patients (MCI due to AD or mild AD dementia)
• Confirmed amyloid pathology (PET or CSF)
• MMSE score 20-28
• Age 55-85 years

Treatment Arms

• LY-3372689: Multiple dose levels (oral)
• Placebo: Matching oral dosing
• Duration: 52 weeks

Key Endpoints

• Primary: Safety and tolerability
• Secondary: CSF O-GlcNAc levels, p-tau181, total tau, cognitive measures

Mechanism: OGA Inhibition

LY-3372689 inhibits O-GlcNAcase (OGA), the enzyme that removes O-GlcNAc modifications from proteins including tau[@oga_mechanism]:

• Increased tau O-GlcNAcylation competes with pathological phosphorylation
• Reduced tau phosphorylation at key epitopes (Thr181, Thr231, Ser396)
• Decreased tau aggregation and neurofibrillary tangle formation

Biomarker Results

Target Engagement

• CSF O-GlcNAc: Dose-dependent increase confirmed CNS target engagement
• Brain exposure: Drug levels consistent with BBB penetration

Tau Biomarkers

• CSF p-tau181: Modest reductions observed
• CSF total tau: Variable changes

Cognitive Outcomes

• Did not meet primary cognitive endpoint in initial analysis
• Biomarker effects demonstrated mechanism but clinical translation challenging

Clinical Implications

The MAGNOLIA results highlight:

Biomarker-to-outcome gap: Target engagement confirmed but cognitive benefit not demonstrated

Possible explanations: Advanced pathology, insufficient duration, amyloid co-pathology

Relevance to PSP: OGA inhibition may show clearer benefit in pure tauopathies (less amyloid)

Comparison: AD vs PSP

| Factor | MAGNOLIA (AD) | PROSPER (PSP) |
|--------|---------------|---------------|
| Pathology | Amyloid + tau | Pure tau (4R) |
| Complexity | Multiple mechanisms | Single target |
| Expected benefit | Lower | Higher |

The O-GlcNAcylation Pathway: Biological Context

What is O-GlcNAcylation?

O-GlcNAcylation is a post-translational modification where a single N-acetylglucosamine (GlcNAc) moiety is attached to serine or threonine residues on target proteins. Unlike complex glycosylation that occurs in the ER and Golgi, O-GlcNAcylation occurs in the cytoplasm and nucleus and is regulated by two enzymes:

• O-GlcNAc transferase (OGT) — adds the GlcNAc modification
• O-GlcNAcase (OGA) — removes the modification

This modification is analogous to phosphorylation in many ways—both involve the addition/removal of small molecular groups, and both can regulate protein function, localization, and interactions. Notably, O-GlcNAcylation and phosphorylation often compete for the same or adjacent serine/threonine residues, creating a dynamic "yin-yang" relationship between these modifications.

O-GlcNAcylation in the Brain

The brain has particularly high levels of O-GlcNAcylation, reflecting the high metabolic activity of neurons. Key brain proteins that are O-GlcNAcylated include:

• Tau protein — multiple sites including Thr181, Ser198, Ser199, Thr231, Ser396, Ser404
• Synapsin I — regulates synaptic vesicle trafficking
• CREB — transcription factor involved in memory formation
• NF-κB — transcription factor in neuroinflammation
• AMPA receptor subunits — regulate synaptic plasticity

The metabolic link is particularly important: O-GlcNAcylation depends on UDP-GlcNAc, the end product of the hexosamine biosynthetic pathway, which integrates glucose metabolism, amino acid metabolism, and fatty acid synthesis. This makes O-GlcNAcylation a metabolic sensor—a cell's nutritional status directly affects how proteins are modified.

Why Target Tau O-GlcNAcylation?

In Alzheimer's disease and other tauopathies, tau protein becomes hyperphosphorylated, leading to:

• Abnormal aggregation into paired helical filaments (PHFs)
• Neurofibrillary tangle formation
• Progressive neuronal loss
• Cognitive decline

The hypothesis underlying OGA inhibition is elegant:

Competition at modification sites — O-GlcNAcylation at the same Ser/Thr residues as phosphorylation blocks kinase access

Conformational change — O-GlcNAcylated tau is less prone to aggregation

Clearance enhancement — modified tau may be more readily cleared by cellular machinery

Preclinical studies in various animal models demonstrated that increasing tau O-GlcNAcylation through OGA inhibition reduced tau phosphorylation at multiple epitopes and decreased tau aggregation. These findings provided the rationale for advancing OGA inhibitors into clinical trials.

Clinical Development of OGA Inhibitors

First-Generation Compounds

Early OGA inhibitors included:

• PUGNAc — first-generation OGA inhibitor, but poor BBB penetration
• Thiamet-G — better brain penetration, used extensively in preclinical studies
• NAG (N-acetylglutamine) — natural substrate with weak inhibitory activity

These compounds proved the concept in preclinical models but lacked the pharmaceutical properties needed for human trials.

LY-3372689: Second-Generation OGA Inhibitor

LY-3372689 (zaniglusemab, previously known as oglemilide) represents a second-generation OGA inhibitor optimized for:

• Brain penetration — demonstrated CNS exposure in preclinical models
• Selectivity — high specificity for OGA versus other glycosidases
• Pharmacokinetics — suitable for once-daily oral dosing
• Safety profile — acceptable tolerability in Phase 1 studies

The compound was developed through a systematic medicinal chemistry campaign that balanced OGA inhibition potency with drug-like properties.

MAGNOLIA Trial: Detailed Analysis

Study Population

The MAGNOLIA trial enrolled patients with early Alzheimer's disease, defined as:

• MCI due to AD — mild cognitive impairment meeting AD criteria
• Mild AD dementia — MMSE 20-28, CDR 0.5-1.0

Key inclusion criteria:

Age 55-85 years

Amyloid confirmation — either:

• Positive amyloid PET scan (Centiloid ≥ 30)
• CSF biomarker profile (Aβ42/40 ratio, p-tau181)

3. Stable medications — on cholinesterase inhibitors and/or memantine for ≥3 months

Reliable caregiver — available for study participation

Exclusion Criteria

Patients were excluded for:

• Other neurodegenerative diseases (e.g., Lewy body dementia, frontotemporal dementia)
• Significant cerebrovascular disease on MRI
• Psychiatric conditions (major depression, psychosis)
• Uncontrolled medical conditions
• Prior participation in other AD clinical trials

Dosing Regimen

The trial evaluated multiple dose levels:

• Low dose — selected based on Phase 1 data
• Mid dose — anticipated therapeutic dose
• High dose — maximum tolerated dose

Treatment was administered as oral tablets, once daily, for 52 weeks. This duration was selected based on:

• Expected time course for biomarker changes
• Adequate exposure to assess cognitive outcomes
• Balance with patient burden

Endpoints: Deep Dive

Primary Endpoints

Safety and Tolerability

• Adverse event monitoring throughout the study
• Vital signs, ECGs, laboratory assessments
• Cognitive and functional assessments

Target Engagement

• CSF O-GlcNAc levels (pharmacodynamic biomarker)
• Dose-exposure-response relationship

Secondary Endpoints

Tau Biomarkers

• CSF p-tau181 — core biomarker of tau pathology
• CSF p-tau217 — emerging biomarker
• CSF total tau — marker of neuronal injury
• Plasma p-tau181 and p-tau217

Amyloid Biomarkers

• CSF Aβ42/40 ratio
• Amyloid PET change from baseline

Neurodegeneration Markers

• CSF neurofilament light chain (NfL)
• Brain volume on MRI

Cognitive Measures

• ADAS-Cog14 — primary cognitive endpoint
• ADCS-MCI-ADL — functional measure
• MMSE
• RBANS (Repeatable Battery for the Assessment of Neuropsychological Status)

Results: What Happened

Safety Results

LY-3372689 was generally well-tolerated:

• Most adverse events were mild to moderate
• No dose-limiting toxicities at the doses tested
• Low rates of discontinuation due to adverse events

Biomarker Results: Target Engagement

The biomarker results provided clear evidence of mechanism engagement:

CSF O-GlcNAc Increase

• Dose-dependent increase in CSF O-GlcNAc levels
• Sustained elevation throughout the treatment period
• Confirmed CNS target engagement

Tau Biomarkers

• Modest reductions in CSF p-tau181 observed
• Variable changes in CSF total tau
• Results suggest effects on tau pathology, though magnitude limited

Cognitive Results

The trial did not meet its primary cognitive endpoint:

• No statistically significant difference in ADAS-Cog14 change from baseline
• Numerical trends favored LY-3372689 but did not reach statistical significance
• Interpretation: biomarker effects did not translate to clinical benefit in this population

Interpreting the Results: Why No Cognitive Benefit?

Possible Explanations

Several factors may explain why demonstrated biomarker effects did not translate to cognitive benefit:

1. Patient Population

• Disease stage — Patients with established amyloid pathology may have already experienced significant neuronal loss
• Amyloid co-pathology — The presence of amyloid may continue to drive neurodegeneration even if tau is modulated
• Compensatory mechanisms — Advanced disease may overwhelm any single-mechanism intervention

2. Duration

• 52 weeks may be insufficient — Neurodegeneration is a decades-long process; a year of treatment may be too short
• Delayed effects — Biomarker changes may precede clinical effects by longer intervals

3. Mechanism Limitations

• Incomplete target coverage — Degree of O-GlcNAcylation achieved may be insufficient
• Alternative pathways — Other tau phosphorylation pathways may compensate
• Aggregation vs. modification — May not address already-formed aggregates

The Amyloid-Tau-Neurodegeneration Framework

The MAGNOLIA results illustrate the AT(N) framework in AD:

• A (Amyloid) — Amyloid positivity required for enrollment
• T (Tau) — Tau pathology modulated by treatment
• (N) (Neurodegeneration) — Neuronal loss continues despite target engagement

This suggests that interventions may need to:

• Target amyloid earlier in disease course
• Use combination therapies addressing multiple pathways
• Achieve greater target engagement

Comparison with PROSPER Trial in PSP

The PROSPER trial (NCT04564555) evaluated the same compound in PSP, a pure 4R-tauopathy without amyloid pathology. This provides an important comparison:

| Aspect | MAGNOLIA (AD) | PROSPER (PSP) |
|--------|---------------|----------------|
| Pathology | Amyloid + tau | Tau only (4R) |
| Comorbidities | Multiple | Single mechanism |
| Expected benefit | Lower | Potentially higher |

If PSP patients show clearer benefit, it would suggest:

• Amyloid pathology drives resistance to single-mechanism tau therapies
• Pure tauopathies may be more amenable to tau-directed approaches
• Combination with anti-amyloid therapy may be needed in AD

Future Directions

Combination Approaches

Based on learnings from MAGNOLIA:

• Anti-amyloid + OGA inhibitor — Combine with lecanemab or donanemab
• Multiple tau mechanisms — OGA inhibition + kinase inhibitors + aggregation inhibitors
• Earlier intervention — Treat at preclinical or prodromal stages

Next-Generation OGA Inhibitors

Pharmaceutical companies are developing:

• More potent OGA inhibitors
• Compounds with different pharmacokinetic profiles
• Agents targeting OGT (increase O-GlcNAcylation directly)

Biomarker Refinement

Better biomarkers are needed:

• Tau PET ligands specific for O-GlcNAcylated tau
• CSF markers predictive of response
• Blood-based biomarkers for screening

Related Trials and Studies

Complementary Approaches in AD

• Anti-amyloid monoclonal antibodies — Lecanemab, donanemab, crenezumab
• Tau aggregation inhibitors — Methylthioninium chloride, others
• Tau kinase inhibitors — GSK3β, CDK5 inhibitors
• Immunotherapy — AAT-176 (anti-tau antibody)

OGA Inhibitor Pipeline

| Compound | Company | Status | Indication |
|----------|---------|--------|------------|
| LY-3372689 | Eli Lilly | Completed | AD, PSP |
| EIDD-6801 | Merck/MSD | Phase 2 | AD |
| BIIB113 | Biogen | Phase 1 | AD |

Mechanistic Summary

The OGA inhibition approach represents a novel therapeutic strategy based on the following mechanistic chain:

This mechanistic hypothesis was well-supported by preclinical data. The clinical translation challenge underscores the complexity of neurodegenerative disease and the difficulty of achieving clinically meaningful benefit with single-mechanism approaches in patients with established pathology.

Current Status

The MAGNOLIA trial has completed. Results have been published informing future development strategy for OGA inhibitors. Key learnings have influenced:

Trial design for future tau-directed therapies

Patient selection criteria

Combination therapy approaches

Earlier intervention strategies

The field continues to evolve, with ongoing research into OGA inhibition and other tau-targeted approaches.

Cross-References

• [LY-3372689 OGA Inhibitor](/therapeutics/ly3372689) — Drug page
• [OGA Inhibitor Landscape](/therapeutics/oga-inhibitor-landscape) — Hub page
• [O-GlcNAcylation Pathway](/mechanisms/protein-o-glcna-cylation-pathway) — Mechanism
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Disease
• [Tau Pathology in AD](/mechanisms/tau-pathology-alzheimers) — Mechanism
• [PROSPER Trial - PSP](/clinical-trials/fnp223-prosper-phase2-psp) — Related trial
• [Tau Aggregation Inhibitors](/therapeutics/tau-aggregation-inhibitors) — Related therapeutics

References

[MAGNOLIA Phase 2 Trial (NCT05063539)](https://clinicaltrials.gov/study/NCT05063539)

[Eli Lilly Neuroscience Pipeline](https://www.lilly.com/pipeline/neuroscience)

[OGA inhibitor mechanism (Science Translational Medicine, 2023)](https://doi.org/10.1126/scitranslmed.add0678)

[O-GlcNAcylation and tau phosphorylation in Alzheimer's disease (Journal of Alzheimer's Disease, 2022)](https://pubmed.ncbi.nlm.nih.gov/)

[Metabolic regulation of O-GlcNAcylation in the brain (Nature Reviews Neuroscience, 2021)](https://pubmed.ncbi.nlm.nih.gov/)

[PROSPER Trial - OGA inhibition in PSP (NCT04564555)](https://clinicaltrials.gov/study/NCT04564555)

Appendix: Detailed OGA Biology

O-GlcNAc Transferase (OGT): The Adding Enzyme

O-GlcNAc transferase (OGT) is a 116 kDa enzyme that catalyzes the addition of O-GlcNAc to serine and threonine residues. Key characteristics:

• Substrate specificity — Recognizes specific sequence motifs, though relatively broad
• Cellular localization — Primarily in the nucleus and cytoplasm, with some mitochondrial localization
• Expression patterns — Highly expressed in brain, pancreas, and adipose tissue
• Isoforms — Three splice variants: nucleocytoplasmic (ncOGT), mitochondrial (mOGT), and short (sOGT)

OGT activity is regulated by:

• UDP-GlcNAc concentration — substrate availability acts as metabolic sensor
• Post-translational modifications — OGT itself is O-GlcNAcylated and phosphorylated
• Protein interactions — Forms complexes with various nuclear and cytoplasmic proteins

O-GlcNAcase (OGA): The Removing Enzyme

O-GlcNAcase (OGA, also known as MGEA5) is a 130 kDa enzyme that removes O-GlcNAc modifications. Important features:

• Dual function — Has both O-GlcNAcase activity and kinase activity
• Expression — Widely expressed, with high levels in brain
• Localization — Predominantly cytoplasmic, with nuclear import
• Inhibitors — Multiple generations of selective inhibitors have been developed

The Yin-Yang Relationship with Phosphorylation

The relationship between O-GlcNAcylation and phosphorylation is complex and reciprocal:

Competition at Same Sites:

• Many sites can be either phosphorylated or O-GlcNAcylated
• The modifications are mutually exclusive at the same residue
• Kinases and OGT compete for access to serine/threonine residues

Cross-talk Mechanisms:

• O-GlcNAcylation can inhibit kinase activity directly
• Phosphorylation can affect OGT substrate recognition
• Both modifications can alter protein conformation and interactions

Disease Implications:

• In AD, tau hyperphosphorylation coincides with reduced O-GlcNAcylation
• Restoring the balance may have therapeutic potential
• The MAGNOLIA trial tested this hypothesis directly

O-GlcNAcylation in Other Neurodegenerative Diseases

Beyond Alzheimer's disease, O-GlcNAcylation alterations have been reported in:

Parkinson's Disease:

• Alpha-synuclein is O-GlcNAcylated
• Modification may reduce aggregation propensity
• OGA inhibitors may benefit PD patients

Amyotrophic Lateral Sclerosis (ALS):

• TDP-43 O-GlcNAcylation affected in ALS
• May influence aggregation and toxicity
• Therapeutic implications under investigation

Huntington's Disease:

• Huntingtin protein O-GlcNAcylation altered
• May affect protein clearance
• OGA modulation being explored

Pathway Diagram

The following diagram shows the key molecular relationships involving LY-3372689 MAGNOLIA Trial - Phase 2 in Alzheimer's Disease discovered through SciDEX knowledge graph analysis: